STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Clinical trials for STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a Pre-Surgery immune booster beat standard care for skin cancer?
Disease control TerminatedThis phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Weekly chemo may be gentler for head and neck cancer patients
Disease control TerminatedThis study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …
Matched conditions: STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC